Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective

BACKGROUND: Based on immunologic phenotypes underlying asthma, use of monoclonal antibody based therapies is becoming the new standard of care for severe, corticosteroid refractory clinical symptoms. Patients may qualify for one or more of these targeted treatments, based on clinical characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeimy, Samira, Tsoulis, Michael William, Hachey, Julie, Kim, Harold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249851/
https://www.ncbi.nlm.nih.gov/pubmed/30479629
http://dx.doi.org/10.1186/s13223-018-0301-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249851/
https://www.ncbi.nlm.nih.gov/pubmed/30479629
http://dx.doi.org/10.1186/s13223-018-0301-6

Ejemplares similares